ClinicalTrials.gg
Not yet recruitingNCT07772934Updated Sep 22, 2026

VBC117First-in-Human Trial of VBC117 in Participants With Advanced Malignant Solid Tumors

A Phase 1/2 interventional study of VBC117 in Advanced Solid Tumors, sponsored by VelaVigo Bio Inc. Not yet recruiting at 12 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-22.

Sponsored by VelaVigo Bio Inc (part of VelaVigo Cayman Limited) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
260
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Detailed Description: This is a multicenter, open-label, multiple-dose, first in human(FIH) Phase 1/2a trial. The Phase 1 portion uses the Bayesian optimal interval (BOIN) design to escalate doses and determine the maximum tolerated dose(MTD) and/or recommended phase 2 dose(RP2D) with potential backfill cohorts. The Phase 2a portion consists of dose optimization followed by cohort expansion to confirm safety and tolerability and further evaluate the efficacy of the selected RP2D in selected solid tumor malignancies treated with VBC117.

02

Conditions studied

  • Advanced Solid Tumors

Keywords

  • Advanced Solid Tumors
  • VBC117
  • Phase 1
  • Phase 2a
  • Dose Escalation
03

In context

Lead sponsor

VelaVigo Bio Inc is the lead sponsor of 5 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The participant or the participant's legally acceptable representative is willing and able to provide a written ICF before initiating any trial procedure.
  2. or cytologically confirmed unresectable advanced/ solid tumor .
  3. At least one as assessed by the investigator according to v1.1 criteria.
  4. Male or female adults (defined as ≥ 18 years of age).
  5. performance status 0-1.
  6. greater than 12 weeks.
  7. Archived tumor tissue sample available or able to undergo a fresh collection.
  8. Adequate organ and bone marrow function.

Exclusion criteria

Exclusion Criteria:

  1. Any unresolved toxicity of Grade ≥2 from previous anti-cancer treatment.
  2. Known or suspected , or spinal cord compression.
  3. Prior treatment with an ADC targeting EGFR x CDH17 bispecific ADC.
  4. Prior treatment with any ADC carrying a topoisomerase I inhibitor (TOP1i) payload.
  5. Has a medical history of interstitial lung diseases or current interstitial lung diseases or who are suspected to have these diseases by imaging at screening.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
260 participants (estimated)

Study arms

  • Experimental
    VBC117 Dose Level 1

    Phase 1 dose escalation and backfill: VBC117 at Dose Level 1

    Drug: VBC117

  • Experimental
    VBC117 Dose Level 2

    Phase 1 dose escalation and backfill: VBC117 at Dose Level 2

    Drug: VBC117

  • Experimental
    VBC117 Dose Level 3

    Phase 1 dose escalation and backfill: VBC117 at Dose Level 3

    Drug: VBC117

  • Experimental
    VBC117 Dose Level 4

    Phase 1 dose escalation and backfill: VBC117 at Dose Level 4

    Drug: VBC117

  • Experimental
    VBC117 Dose Level 5

    Phase 1 dose escalation and backfill: VBC117 at Dose Level 5

    Drug: VBC117

  • Experimental
    VBC117 Dose Level RP2D

    Phase 2a expansion cohort: VBC117 at RP2D across tumor-specific cohorts

    Drug: VBC117

Interventions

  • DrugVBC117

    VBC117 is a epidermal growth factor receptor (EGFR)x Cadherin-17 (CDH17) bispecific antibody-drug conjugate (ADC).

06

What researchers measure

Primary outcomes

  1. Incidence of AEs

    Number of patients with Adverse Events(AEs)by system organ class and preferred term

    Time frame: From time of Informed Consent to 30 days post last dose of VBC117

  2. Incidence of DLTs

    Incidence of dose-limiting toxicities (DLT) as defined in the protocol

    Time frame: From time of first dose of VBC117 to end of DLT period (approximately 21 days)

  3. Incidence of SAEs

    Number of patients with Serious Adverse Events(SAEs)by system organ class and preferred term

    Time frame: From time of Informed Consent to 30 days post last dose of VBC117

  4. Incidence of TEAE leading to dose modification or discontinuation

    Number of patients with treatment-emergent adverse event (TEAE) leading to dose modification or discontinuation by system organ class and preferred term

    Time frame: From time of Informed Consent to 30 days post last dose of VBC117

  5. objective response rate (ORR)

    The percentage or number of patients with a confirmed investigator assessed complete or partial response according to response criteria in solid tumours

    Time frame: From first dose of VBC117 to disease progression or death, up to approximately 2 years

07

Study locations

12 sites
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2026; primary completion for Feb 2029, 30 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2026
First posted
Aug 19, 2026
StartEst.
Aug 24, 2026
Primary completionEst.
Feb 27, 2029
CompletionEst.
May 28, 2029
Last update
Sep 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07772934
Lead sponsor
VelaVigo Bio Inc
Responsible party
Sponsor
First posted
Aug 19, 2026
Start date
Aug 24, 2026 (estimated)
Primary completion
Feb 27, 2029 (estimated)
Completion
May 28, 2029 (estimated)
Last update
Sep 22, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion